Search News
| 101.50 Delayed Data As of Sep 18 |  0.00 / 0.00%Today’s Change | 92.38 Today|||52-Week Range 115.80 | -6.37% Year-to-Date |
| Merck or Pfizer: Which is the Better Large-Cap Pharma Stock? Sep 20 / Zacks.com - Paid Partner Content | Pfizer's Drug Combo Betters Survival in Kidney Cancer Study Sep 12 / Zacks.com - Paid Partner Content |
| 3 Lung Cancer Stocks That Could End September on a High Note Sep 13 / MotleyFool.com - Paid Partner Content |
| Previous close | 101.50 |
| Today’s open | 101.50 |
| Day’s range | 101.50 - 101.50 |
| Volume | 50 |
| Average volume (3 months) | 265 |
| Market cap | $13.1B |
| Earnings growth (last year) | +62.60% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +4.02% |
| P/E ratio | 15.7 |
| Price/Sales | 2.71 |
| Price/Book | 2.62 |
| No competitors data available. |
| Next reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $17.3B |
| Annual profit (last year) | $2.9B |
| Net profit margin | 16.96% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman-Executive Board & CEO Stefan Oschmann |
Chief Financial Officer Marcus Kuhnert |
Corporate headquarters Darmstadt, Hessen |
